|Bid||0.00 x 3000|
|Ask||0.00 x 1000|
|Day's Range||52.80 - 53.15|
|52 Week Range||17.75 - 55.29|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||44.72|
On January 29, Sanofi announced its acquisition of Ablynx for $4.8 billion, and it announced the completion of the acquisition on June 19. The acquisition was one of two announced in January to advance its blood disorder portfolio. The other acquisition was of Bioverative.
Small and large cap stocks are widely popular for a variety of reasons, however, mid-cap companies such as Ablynx NV (EBR:ABLX), with a market cap of €3.38b, often get neglectedRead More...
The most recent earnings release Ablynx NV’s (ENXTBR:ABLX) announced in December 2017 suggested that losses became smaller relative to the prrior year’s level – great news for investors Below, I’veRead More...
Small and large cap stocks are widely popular for a variety of reasons, however, mid-cap companies such as Ablynx NV (ENXTBR:ABLX), with a market cap of €3.38B, often get neglectedRead More...
LONDON, UK / ACCESSWIRE / May 16, 2018 / If you want access to our free research report on Sanofi American Depositary Shares (NYSE: SNY) ("Sanofi"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=SNY as the Company's latest news hit the wire. On May 14, 2018, the Company along with Ablynx NV (NASDAQ: ABLX) together reported the successful results of the initial tender offer period of Sanofi's previously announced tender offers to acquire all of the outstanding shares, including shares represented by American Depositary Shares (ADSs), warrants, and convertible bonds of Ablynx.
Today, I will be analyzing Ablynx NV’s (ENXTBR:ABLX) recent ownership structure, an important but not-so-popular subject among individual investors. A company’s ownership structure is often linked to its share performanceRead More...
If you are a shareholder in Ablynx NV’s (ENXTBR:ABLX), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of your portfolioRead More...
Protagonist Therapeutics, Inc. (PTGX) is drawing a lot of attention in the biotechnology space at the moment on the back of the release of some data rooted in a clinical trial program set up to investigate an asset called PTG-100. Tahis is the lead asset from Protagonist’s development pipeline and, unfortunately for the company and […] The post Here’s What’s Moving Protagonist And Ablynx Right Now appeared first on Market Exclusive.
Ablynx NV’s (ENXTBR:ABLX) announced its latest earnings update in December 2017, which indicated that losses became smaller relative to the prrior year’s level – great news for investors Today IRead More...
Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Ablynx NV (ENXTBR:ABLX) with a market-capitalization of €3.30B, rarely draw their attention. Despite this, the two otherRead More...
A week after unveiling an $11.6-billion deal for Bioverativ, Sanofi said it was spending another $4.8 billion to acquire Belgian biotech firm Ablynx.
U.S. stock futures trade lower, Donald Trump's national security advisers look at building a 5G network, and France's Sanofi buys Belgian biotech Ablynx.
Sanofi agreed to buy Belgium’s Ablynx NV for 3.9 billion euros ($4.8 billion), leapfrogging an unsolicited bid from the French drugmaker’s fierce rival, Novo Nordisk A/S, to gain a potential blockbuster ...
It began almost three decades ago with a container of frozen camel blood in Belgium, took a detour through Morocco and progressed to a stock listing in New York last year. The latest chapter in Ablynx ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Ablynx NV Here are 5 ETFs with the largest exposure to ABLX-US. Comparing the performance and risk of Ablynx NV with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis Ablynx NV reports financial results for the half-year ended June 30, 2017. We analyze the earnings along side the following peers of Ablynx NV – Medivir AB Unsponsored ADR and MorphoSys AG Sponsored ADR (MVRBY-US and MPSYY-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 37.94 ... Read more (Read more...)
Jan.29 -- Ablynx NV agreed to a takeover bid from Sanofi worth about $4.8 billion, snubbing a lower offer from Novo Nordisk A/S. Bloomberg’s Benedikt Kammel has more on "Bloomberg Markets."
Jan.08 -- Jesper Brandgaard, chief financial officer at Novo Nordisk, discusses the company's unsolicited $3.1 billion bid for Ablynx NV. He speaks with Francine Lacqua on "Bloomberg Surveillance."